Abstract:Background: HBV-specific cytotoxic T lymphocyte (CTL) activity is believed to play a critical role in controlling HBV infection. The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway manipulates cell fate decisions in many different cell types by regulating the activity of downstream effectors. We have previously testified that the fusion protein of CTP-HBcAg18-27-Tapasin could enter the cytoplasm of dendritic cells and efficiently induce robust specific CTL response in vitro.Objectives: In the present study, we evaluated specific CTL response and the level of apoptosis of CD8+ T cells induced by CTP-HBcAg18-27-Tapasin in HLA-A2 transgenic mice (H-2Kb). Meanwhile, we preliminary investigated PI3K, phosphorylation level of Akt, and mammalian target of rapamycin (mTOR) as positive regulator of the magnitude and effector function of the hepatitis B virus-specific cytotoxic T lymphocytes in HLA-A2 transgenic mice.Materials and Methods: HLA-A2 transgenic mice were immunized by intramuscular injection in the hind legs three times at one-week intervals with PBS, CTP-HBcAg18-27-Tapasin (50 mu g), CTP-HBcAg18-27 (50 mu g), HBcAg18-27-Tapasin (50 mu g), and HBcAg18-27 (50 mu g). One week after the last immunization, mice were sacrificed and splenocytes were harvested in strile condition. The specific CTL response was analyzed by flow cytometry and enzyme linked immunosorbent assay (ELISA); the expression of (PI3K)/Akt signaling was detected by RTPCR and western blot.Results: The results showed that CTP-HBcAg18-27-Tapasin significantly increased the percentages of IFN-gamma(+) CD8 alpha(+) T cells, the numbers of these polyfunctional triple-cytokine-producing (IFN-gamma, TNF-alpha, and IL-2) CD8(+)T cells, the secretion of cytokine IFN-gamma, IL-2, and TNF-alpha, while in comparison to control group, it significantly decreased the percentage of apoptotic CD8(+) T cells in HLA-A2 transgenic mice. Moreover, the expression of PI3K, P-Akt, and P-mTOR was significantly upregulated in CTP-HBcAg18-27-Tapasin group compared with control groups.Conclusions: In conclusion, CTP-HBcAg18-27-Tapasin could reduce apoptosis of CD8(+) T cells, increase the percentages of IFN-gamma(+) CD8a(+) T cells, and elicit cell-mediated immunity in HLA-A2 transgenic mice; these processes were associated with activation of the PI3K/Akt signaling pathway.

Pmhc/scfv Fusion Protein Mediates Killing of Tumor Cells by Viral Specific Cytotoxic T Cells

Viral Specific Cytotoxic T Cells Inhibit the Growth of TfR-expressing Tumor Cells with Antibody Targeted Viral Peptide/hla-A2 Complex

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity.

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes

Experimental study on the enhancement of killing effect of LAK-like cells and ADCC induced by anti-human P185erbB2 scFv-Fc-IL-2 fusion protein and its mechanisms

Potent Killing of HBV-related Hepatocellular Carcinoma by a Chimeric Protein of Anti-Hbsag Single-Chain Antibody and Truncated Bid

A Novel Fusion Antibody Exhibits Antiangiogenic Activity and Stimulates NK Cell-mediated Immune Surveillance Through Fused NKG2D Ligand.

Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma.

Targeting activity of a TCR/IL-2 fusion protein against established tumors

The Fusion Protein of Ctp-Hbcag18-27-Tapasin Mediates the Apoptosis of Cd8+T Cells and Cd8+T Cell Response in Hla-A2 Transgenic Mice

[Hbcag-Specific CTL Response Induced by PTD-HBcAg Fusion Protein to Inhibit HBV Replication in Vitro].

Cytotoxic Effects of Gastric Cancer Cell-Dc Fusion Vaccines

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

[Construction of Genetically Modified Dendritic Cell Vaccine Expressing Bcr/abl Fusion Gene and Inducing Specific Cytotoxic T Lymphocytes to Kill K562 Cells in Vitro].

Apoptosis Effect of Immunizations with Fusions of Dendritic Cells and HCC Cells in Mice

[Application of Fusion Gene Mgm-Csf/hil-2 to Specific Immunotherapy Induced by Hepatic Tumor Cell Vaccine].

Efficient Growth Inhibition of ErbB2-overexpressing Tumor Cells by Antierbb2 ScFv-Fc-IL-2 Fusion Protein in Vitro and in Vivo

Immunity Against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine Β-Defensin 2 and Mflk-1

Eliciting specific antitumor immunity against hepatocellular carcinoma in vitro by fusions of HCC patient-derived dendritic cells with HCC cells